Back to newsroom
News
Results of Clinical Trial PA.6 Announced in Chicago

June 9, 2019

Clinical trial results performed in Canada and France using mFOLFIRINOX have shown that patients who undergo surgical removal of pancreatic cancer cells lived on average, 20 months longer than those who received gemicitabine. – Global News

Be part of the force driving answers for this devastating disease.

Make a donation towards pancreatic cancer research and support programs.

donate today

Keep in the loop:

Read more PCNA News:

discover more

June 13, 2025

Research
Research Update – NeoPancONE Study Results Presented at ASCO 2025

June 26, 2025

Research
Our Impact in 2024: A New Era

May 23, 2025

Research
The Stratford Beacon Herald: 50 cyclists set to pass through Stratford for pancreatic cancer awareness